AbbVie Inc. (AbbVie) has announced its 2024 Annual Meeting of Stockholders to be held virtually on May 3, 2024. The meeting will invite stockholders to vote on the election of five directors, the ratification of Ernst & Young LLP as AbbVie's independent registered public accounting firm for 2024, advisory votes on executive compensation and the frequency of future stockholder advisory votes on executive compensation, and a management proposal to eliminate supermajority voting. Additionally, three stockholder proposals will be considered if properly presented. The meeting will also address any other matters that may properly come before it, including three stockholder proposals if presented. Stockholders as of the record date, March 4, 2024, are entitled to notice of and to vote at the meeting. AbbVie's board recommends voting for the election of the nominated directors, for the ratification of Ernst & Young LLP, for the approval of named executive officers' compensation, for annual advisory approvals of executive compensation, for the management proposal to eliminate supermajority voting, and against each of the stockholder proposals.

AbbVie Inc. (AbbVie) has announced its 2024 Annual Meeting of Stockholders to be held virtually on May 3, 2024. The meeting will invite stockholders to vote on the election of five directors, the ratification of Ernst & Young LLP as AbbVie's independent registered public accounting firm for 2024, advisory votes on executive compensation and the frequency of future stockholder advisory votes on executive compensation, and a management proposal to eliminate supermajority voting. Additionally, three stockholder proposals will be considered if properly presented. The meeting will also address any other matters that may properly come before it, including three stockholder proposals if presented. Stockholders as of the record date, March 4, 2024, are entitled to notice of and to vote at the meeting. AbbVie's board recommends voting for the election of the nominated directors, for the ratification of Ernst & Young LLP, for the approval of named executive officers' compensation, for annual advisory approvals of executive compensation, for the management proposal to eliminate supermajority voting, and against each of the stockholder proposals.